Announcements Trials
Browse Landscape

Phase

Phase 3 15Phase NA 11Phase 1 11Phase 2/3 7Phase 2 5Phase 1/2 5Phase EARLY_PHASE1 4Phase 4 3

Status

Recruiting 5Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 156Neoplasms 115Colorectal Neoplasms 98Breast Neoplasms 93Pancreatic Neoplasms 81Neoplasm Metastasis 81Leukemia, Myeloid, Acute 79Recurrence 76Prostatic Neoplasms 74Ovarian Neoplasms 74Melanoma 74Multiple Myeloma 66Stomach Neoplasms 59Lung Neoplasms 56Squamous Cell Carcinoma of Head and Neck 55Triple Negative Breast Neoplasms 50Glioblastoma 49Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Myasthenia Gravis × Clear all
NCT07596901 2026-05-19

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Aurinia Pharmaceuticals Inc.

Phase 1/2 Recruiting
81 enrolled

Myasthenia Gravis

NCT06704269 2026-04-06

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Novartis

Phase 1/2 Recruiting
15 enrolled

Myasthenia Gravis

NCT07250750 2026-02-11

Synergy-MG

ImmunAbs Inc.

Phase 1/2 Recruiting
96 enrolled

Myasthenia Gravis

NCT07022197 2025-06-15

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Tianjin Medical University General Hospital

Phase 1/2 Recruiting
27 enrolled

Myasthenia Gravis, Myositis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06106672 2025-02-13

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

COUR Pharmaceutical Development Company, Inc.

Phase 1/2 Recruiting
54 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡